Senate Amendment A01662
S0804B0902A01662 NAD:CDM 09/03/25 #90 A01662AMENDMENTS TO SENATE BILL NO. 804Sponsor: SENATOR FARRYPrinter's No. 902Amend Bill, page 2, line 5, by striking out all of said lineAmend Bill, page 4, lines 5 through 14, by striking out all of said lines and inserting "Intentionally added DEHP." DEHP that a manufacturer has intentionally added to a product and that has a functional or technical effect on the product.Amend Bill, page 5, lines 15 through 26, by striking out all of said lines and inserting "Unintentionally added DEHP." DEHP in an i ntravenous solution container or intravenous tubing product that is not used for functional or technical effect on the product.Amend Bill, page 5, lines 28 and 29, by striking out "Beginning January 1, 2027 " and inserting Except as provided under subsection (f), beginning January 1, 2030Amend Bill, page 6, lines 2 through 24, by striking out all of said lines and inserting (b) Intravenous tubing.--Beginning January 1, 2035, a person may not manufacture, sell or distribute intravenous tubing made with intentionally added DEHP.(c) Replacement.--A person may not replace DEHP with another ortho-phthalate in a new or revised medical device.(d) Unintentionally added DEHP.--An intravenous solution container or intravenous tubing product may not have unintentionally added DEHP present at a quantity at or above 0.1% weight per weight (w/w).(e) Exemptions.--The following items, as described in 21 CFR (relating to food and drugs), are exempt from the provisions of this section:(1) Human blood collection and storage bags.(2) Apheresis and cell therapy blood kits and bags, 2025/90NAD/SB0804A01662 - 1 -12345678910111213141516171819202122232425262728293031
including integral tubing.(f) Extension.--A person, due to pending United States Food and Drug Administration approval for the DEHP-free intravenous solution container or due to the manufacturer not having adequate equipment to manufacture the DEHP-free intravenous solution container, shall meet the requirement under subsection (a) by January 1, 2032, if all of the following conditions are met:(1) The person notified its customers in this Commonwealth, no later than July 1, 2026, that the person has commenced development of the DEHP-free intravenous solution container to meet the requirements of this section.(2) The person provides notice to its customers in this Commonwealth and posts to its publicly accessible Internet website, no later than January 1, 2028, that the person will not meet the deadline imposed under subsection (a).2025/90NAD/SB0804A01662 - 2 -12345678910111213141516
Official text from the Pennsylvania Legislature. Formatting has been adapted for reading on Ratifi.